How This Evidence Evolved
Testosterone Replacement CV Safety
From safety concerns to definitive cardiovascular outcome data
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Follow-up studies, subgroup analyses, and real-world validation
Sexual activity (Psychosexual Daily Questionnaire) at 1 year: testosterone vs placebo, increased (P<0.001); 6-minute walk gain of 50 m or more in all trials: 20.5% vs 12.6% (P=0.003), not significant within the Physical Function Trial
High-grade prostate cancer over 14,304 person-years: testosterone 5 of 2596 (0.19%) vs placebo 3 of 2602 (0.12%) (HR 1.62, 95% CI 0.39-6.77; P = .51)
Integration into clinical practice guidelines and recommendations
Recommends diagnosing hypogonadism only in men with symptoms and signs of testosterone deficiency and unequivocally and consistently low serum testosterone; testosterone therapy for symptomatic deficiency; monitoring of symptoms, adverse effects, serum testosterone, hematocrit and prostate cancer risk during the first year
Consensus that testosterone therapy prescribed to appropriately selected patients and monitored regularly is safe from a cardiovascular standpoint; in agreement with recent US FDA label changes for testosterone products
Current standard of care and ongoing research directions
Landmark Trials in This Story
Adverse events associated with testosterone administration
Subjects with cardiovascular-related adverse events: testosterone 23 vs placebo 5; stopped early by DSMB
Cardiovascular Safety of Testosterone-Replacement Therapy
MACE (CV death, nonfatal MI, nonfatal stroke): HR 0.96 (95% CI 0.78-1.17; noninferiority confirmed)
Effects of Testosterone Treatment in Older Men.
Sexual activity (Psychosexual Daily Questionnaire) at 1 year: testosterone vs placebo, increased (P<0.001); 6-minute walk gain of 50 m or more in all trials: 20.5% vs 12.6% (P=0.003), not significant within the Physical Function Trial
Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial.
High-grade prostate cancer over 14,304 person-years: testosterone 5 of 2596 (0.19%) vs placebo 3 of 2602 (0.12%) (HR 1.62, 95% CI 0.39-6.77; P = .51)
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Recommends diagnosing hypogonadism only in men with symptoms and signs of testosterone deficiency and unequivocally and consistently low serum testosterone; testosterone therapy for symptomatic deficiency; monitoring of symptoms, adverse effects, serum testosterone, hematocrit and prostate cancer risk during the first year
Cardiovascular safety of testosterone therapy-Insights from the TRAVERSE trial and beyond: A position statement of the European Expert Panel for Testosterone Research.
Consensus that testosterone therapy prescribed to appropriately selected patients and monitored regularly is safe from a cardiovascular standpoint; in agreement with recent US FDA label changes for testosterone products
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.